Maxcyte (MXCT) EBIT (2020 - 2026)

Maxcyte (MXCT) has 7 years of EBIT data on file, last reported at -$6.2 million in Q1 2026.

• On a quarterly basis, EBIT rose 49.69% year-over-year to -$6.2 million in Q1 2026; TTM through Mar 2026 was -$45.8 million, a 10.6% increase from a year earlier, with the FY2025 full-year figure at -$51.9 million, down 1.37% from the prior year.
• EBIT for Q1 2026 stood at -$6.2 million, up from -$11.2 million in the prior quarter.
• Over the last five years, EBIT for MXCT reached as high as -$4.2 million in Q1 2022 and fell as low as -$14.2 million in Q2 2025.
• Historically, EBIT has averaged -$10.9 million across 5 years, with a median of -$12.3 million in 2024.
• Across the five-year window, EBIT plunged 216.85% in 2023 and jumped 49.69% in 2026, its largest moves.
• Year by year, EBIT stood at -$6.8 million in 2022, then slipped by 19.93% to -$8.1 million in 2023, then plunged by 59.35% to -$12.9 million in 2024, then climbed by 12.98% to -$11.2 million in 2025, then surged by 44.9% to -$6.2 million in 2026.
• Per Business Quant data, the three most recent EBIT figures were -$6.2 million in Q1 2026, -$11.2 million in Q4 2025, and -$14.1 million in Q3 2025.